Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ST-3
- Development stage
- Preclinical
- Lead developer
- University of Kansas Medical Center
- Modality
- Small Molecules
01
Overview
ST-3 is a small molecule inhibitor of the RNA-binding protein HuR (ELAV-like protein 1), identified and characterized by researchers at the University of Kansas Medical Center. HuR is a key regulator that stabilizes mRNAs associated with tumor progression, metastasis, and chemoresistance. ST-3 works by directly binding to HuR and disrupting its interaction with target mRNAs, such as Snail, thereby inhibiting epithelial-mesenchymal transition (EMT) and the maintenance of cancer stem cells (CSCs). In preclinical models of pancreatic cancer, ST-3 has shown efficacy in reducing cell migration, invasion, and spheroid formation, particularly in cell lines with high HuR expression.
02
Targets
ELAVL1 (Human Antigen R)
Beyond the preview
Go deeper on ST-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ST-3.